Welcome to our dedicated page for Twist Bioscience Corporation news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience Corporation stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience (TWST) highlights a critical need for innovative enterprise storage technologies, according to a new white paper. Key points include:
- Projected storage demand could exceed 25 zettabytes by 2030, outpacing available capacity.
- Approximately 75% of stored data is 'cold', rarely accessed, and likely never deleted.
- DNA data storage is proposed as a solution, promising high density, cost efficiency, and sustainability.
The company aims to lead in this space, addressing a projected $7 billion unmet storage demand.
Twist Bioscience Corporation (NASDAQ: TWST) and Biotia, Inc. have received an expanded Emergency Use Authorization (EUA) from the FDA for their SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. This authorization enhances COVID-19 patient management by allowing for the identification of specific genomic mutations and viral lineages. Originally developed in 2020 and authorized in March 2021, the assay provides crucial insights into evolving variants like Omicron. The assay’s hybridization capture-based method improves mutation detection, aiding clinicians in treatment decisions.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CFO Jim Thorburn and CCO Patrick Finn will host a fireside chat at the UBS Genomics 2.0 and Medtech Innovations Summit on August 9 at 2:00 p.m. PT in Dana Point, California. The event will be webcast live, and a replay will be available for 30 days post-event. Twist Bioscience specializes in synthetic DNA manufacturing using its innovative silicon platform, offering products for various industries including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) will release its fiscal 2022 third quarter results on August 5, 2022, before market opening. A conference call will follow at 8:00 a.m. ET for analysts and investors to discuss the results and provide business updates. Twist, known for its innovative synthetic DNA manufacturing on silicon chips, continues to expand its offerings, including synthetic genes and tools for next-generation sequencing. Financial results will be posted on their website prior to the call.
Twist Bioscience Corporation (NASDAQ: TWST) has launched synthetic DNA controls for the human monkeypox virus, enhancing its portfolio of next-generation sequencing (NGS) applications for viral diseases. These controls, based on two known clades of the monkeypox virus, will improve the quality and validation of NGS and PCR assays. Twist's synthetic DNA controls cover over 80% of the viral genome and facilitate research and diagnostic tests. The new products align with the company’s commitment to addressing emerging public health concerns.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with DNAnexus to integrate their platforms, enhancing the design, validation, and commercialization of NGS-based diagnostic tests. This partnership enables Twist customers to utilize DNAnexus' cloud-based biomedical data analysis tools alongside Twist’s NGS Methylation Detection and Unique Molecular Identifier Adapter Systems. The collaboration aims to streamline data analysis, ultimately accelerating research in rare diseases and cancer diagnostics.
Twist Bioscience Corporation has announced the opening of its new facility in Quincy, Massachusetts, enhancing its in vivo antibody discovery capacity. This growth aligns with their strategy to accelerate antibody discovery for biopharma partners. The Twist Boston location, previously acquired in November 2021, is equipped with advanced tools, including four Berkeley Lights Beacon® Optofluidic Platforms, aimed at increasing screening capacity. The company plans to further expand its site to support future growth in biologics and diagnostics.
Twist Bioscience Corporation (NASDAQ: TWST) has partnered with Ildong Pharmaceutical to license a suite of VHH antibody libraries for immuno-oncology applications. The agreement, marking Twist's first collaboration with a South Korean company, includes an upfront payment, annual fees, and royalties on product sales. The VHH libraries, known for their small size and versatility, enable the development of novel therapies targeting various diseases. This partnership aims to enhance Ildong's pipeline and supports Twist's strategic expansion in the Asia-Pacific region.
Twist Bioscience Corporation (NASDAQ: TWST) announced that Steffen Hellmold, Senior VP of Business Development for Data Storage, will present at the Fujifilm 12th Annual Global IT Executive Summit in San Diego, CA, from June 22-25, 2022. Hellmold's presentation, titled "Scaling up from Data Lakes to Data Oceans," is scheduled for June 23, 3:15-3:45 PM PT. The summit focuses on data management trends and how DNA data storage can address exponential data growth. Twist Bioscience leverages a proprietary DNA synthesis platform for various applications across industries, including healthcare and agriculture.
Twist Bioscience has launched the Twist MRD Rapid 500 Panel, priced at
This innovative solution targets up to 500 genomic regions and allows researchers to receive tailored panels in as little as five days, significantly improving the monitoring of cancer treatment responses.
The product integrates with standard NGS workflows, potentially enhancing sequencing sensitivity while aiding in disease surveillance.
FAQ
What is the current stock price of Twist Bioscience Corporation (TWST)?
What is the market cap of Twist Bioscience Corporation (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
